Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study...

by Philip S Helliwell, Prasheen Agarwal, Christopher T Ritchlin, Alexa P Kollmeier, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu, Qing C Zuraw, Yusang Jiang, Bei Zhou, Yanli Zhuang, May Shawi
Published 2021-04-01

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with ac...

by Proton Rahman, Philip J. Mease, Philip S. Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P. Kollmeier, Elizabeth C. Hsia, Bei Zhou, Xiwu Lin, May Shawi, Chetan S. Karyekar, Chenglong Han
Published 2021-07-01